Literature DB >> 15820948

Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype.

Rita Maccario1, Marina Podestà, Antonia Moretta, Angela Cometa, Patrizia Comoli, Daniela Montagna, Liane Daudt, Adalberto Ibatici, Giovanna Piaggio, Sarah Pozzi, Francesco Frassoni, Franco Locatelli.   

Abstract

BACKGROUND AND OBJECTIVES: Experimental evidence and preliminary clinical studies have demonstrated that human mesenchymal stem cells (MSC) have an important immune modulatory function in the setting of allogeneic hematopoietic stem cell (HSC) transplantation. We extended the evaluation of mechanisms responsible for the immune regulatory effect derived from the interaction of human MSC with cells involved in alloantigen-specific immune response in mixed lymphocyte culture (MLC). DESIGN AND METHODS: Dendritic cell (DC) differentiation, T- and natural killer (NK)-lymphocyte expansion, alloantigen-specific cytotoxic activity and differentiation of CD4+ T-cell subsets co-expressing CD25 and/or CTLA4 molecules were assessed, comparing the effect observed using third-party MSC with that obtained employing MSC autologous to the MLC responder.
RESULTS: We found that human MSC strongly inhibit alloantigen-induced DC1 differentiation, down-regulate alloantigen-induced lymphocyte expansion, especially that of CD8+ T cells and of NK lymphocytes, decrease alloantigen-specific cytotoxic capacity mediated by either cytotoxic T lymphocytes or NK cells and favor the differentiation of CD4+ T-cell subsets co-expressing CD25 and/or CTLA4. More effective suppressive activity on MLC-induced T-cell activation was observed when MSC were third-party, rather than autologous, with respect to MLC-responder cells. INTERPRETATION AND
CONCLUSIONS: Our results strongly suggest that MSC-mediated inhibition of alloantigen-induced DC1 differentiation and preferential activation of CD4+ CD25+ T-cell subsets with presumed regulatory activity represent important mechanisms contributing to the immunosuppressive activity of MSC. Collectively, these data provide immunological support for the use of MSC to prevent immune complications related to both HSC and solid organ transplantation and to the theory that MSC are universal suppressors of immune reactivity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15820948

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  177 in total

Review 1.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

2.  Adipose-derived mesenchymal stromal cells from genetically modified pigs: immunogenicity and immune modulatory properties.

Authors:  Goutham Kumar; Hidetaka Hara; Cassandra Long; Humza Shaikh; David Ayares; David K C Cooper; Mohamed Ezzelarab
Journal:  Cytotherapy       Date:  2012-01-23       Impact factor: 5.414

3.  Biological individuality and the new frontiers of immunological tolerance in hematopoietic stem cell transplantation.

Authors:  Giuseppe Roberto Burgio; Marco Zecca; Patrizia Comoli; Rita Maccario
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

Review 4.  Advancing islet transplantation: from engraftment to the immune response.

Authors:  R F Gibly; J G Graham; X Luo; W L Lowe; B J Hering; L D Shea
Journal:  Diabetologia       Date:  2011-08-10       Impact factor: 10.122

Review 5.  Factors governing the immunosuppressive effects of multipotent mesenchymal stromal cells in vitro.

Authors:  Aleksandra Gornostaeva; Elena Andreeva; Ludmila Buravkova
Journal:  Cytotechnology       Date:  2015-08-13       Impact factor: 2.058

6.  Immunomodulation of endothelial differentiated mesenchymal stromal cells: impact on T and NK cells.

Authors:  Reine El Omar; Yu Xiong; Gabriel Dostert; Huguette Louis; Monique Gentils; Patrick Menu; Jean-François Stoltz; Émilie Velot; Véronique Decot
Journal:  Immunol Cell Biol       Date:  2015-10-29       Impact factor: 5.126

7.  Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC).

Authors:  Igor B Resnick; Claudine Barkats; Michael Y Shapira; Polina Stepensky; Allan I Bloom; Avichai Shimoni; David Mankuta; Nira Varda-Bloom; Lyudmila Rheingold; Moshe Yeshurun; Bella Bielorai; Amos Toren; Tsila Zuckerman; Arnon Nagler; Reuven Or
Journal:  Am J Blood Res       Date:  2013-08-19

8.  Mesenchymal stromal cells versus betamethasone can dampen disease activity in the collagen arthritis mouse model.

Authors:  E S M El-Denshary; L A Rashed; M Elhussiny
Journal:  Clin Exp Med       Date:  2013-08-30       Impact factor: 3.984

9.  Mesenchymal stem/stromal cells protect the ocular surface by suppressing inflammation in an experimental dry eye.

Authors:  Min Joung Lee; Ah Young Ko; Jung Hwa Ko; Hyun Ju Lee; Mee Kum Kim; Won Ryang Wee; Sang In Khwarg; Joo Youn Oh
Journal:  Mol Ther       Date:  2014-08-25       Impact factor: 11.454

10.  Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors.

Authors:  Maria Antonietta Avanzini; Maria Ester Bernardo; Angela Maria Cometa; Cesare Perotti; Nadia Zaffaroni; Francesca Novara; Livia Visai; Antonia Moretta; Claudia Del Fante; Raffaella Villa; Lynne M Ball; Willem E Fibbe; Rita Maccario; Franco Locatelli
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.